

**AABM Annual Meeting - 2013-2014 Steering Committee**

- Larry Couture, City of Hope (Chair)
- Lorraine Matheson, Indiana University
- Han Vanderloo, Cincinnati Children's Hospital
- Fraser Wright, Children's Hospital of Philadelphia
- Elizabeth Murray, Marshall University
- Isabelle Riviere, Memorial Sloan Kettering

**AABM Individual Membership**

The mission of AABM is to establish a network of non-profit, academic-based biologics manufacturers, where professionals in the field can come together to share expertise amongst members, discuss Manufacturing, QA, and QC challenges, and share experiences and resources. Become an AABM Member and register on line at:

<http://www.aabmonline.org/users/register>

**Have you contributed facility SOPs to AABM?**

Email them to: [aabm@aabmonline.org](mailto:aabm@aabmonline.org)

Log on to  
the Library

**FEATURED FACILITY**

University of Florida Powell Gene Therapy Center  
Human Applications Laboratory (HAL)



**Facility Director**  
**Barry Byrne, M.D., Ph.D.**

The primary mission of the Powell Gene Therapy Center is to merge molecular genetics research and health care delivery by developing new therapeutic strategies for the treatment of human diseases. The Center has been instrumental in the development of newer, safer and potent agents for the delivery of therapeutic genes to patients with genetic diseases using vectors derived from adeno-associated virus. The Human Applications Laboratory (HAL) is a GMP manufacturing facility located in the Powell Gene Therapy. The production facility occupies approximately 1900 square feet and consists of two suites with 14 separate

rooms. Each suite is designed to function independently and each contains two production rooms (Class 10,000), a staging and storage area (Class 10,000) and entrance and exit vestibules (Class 100,000). Production Suite A is used for cell processing and is used for the generation of cell banks as well as cellular therapy products. Production Suite B is used for the purification, filtration and aseptic fill of recombinant viral vectors.

A dedicated quality control unit provides all environmental monitoring, in-process, final product testing as well as ongoing stability testing. The operation is supported by an independent quality assurance unit. HAL operates in conjunction with the Vector Core for full process and test development and the Toxicology Core for preclinical toxicology and biodistribution services.

